Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1530)	10/4/2015 5:38:04 PM
From: Strong Long	Respond to of 2026

PR I agree. I would much prefer a cash infusion without additional dilution. I also believe you are right about the provision you mention, as it relates to the sale of shares to the general public. Under the Subscription Agreements, certain of the purchasers related to Sarissa Capital Management LP (the "Sarissa Investors") have preemptive rights to participate in future equity issuances by the Company, subject to certain exceptions, so as to maintain the Sarissa Investors' then-current percentage beneficial ownership of the Company's common stock Preemptive right - A privilege extended to select shareholders of a corporation that will give them the right to purchase additional shares in the company before the general public has the opportunity in the event there is a seasoned offering.